Black Diamond Therapeutics reported a net income of $56.542 million for Q1 2025, a substantial improvement from a net loss of $18.225 million in Q1 2024, primarily due to a $70.0 million upfront payment from a global licensing agreement with Servier Pharmaceuticals LLC. Operating expenses decreased, contributing to the positive financial performance.

Black Diamond Therapeutics reported a net loss of $16.0 million for the fourth quarter of 2024, an improvement from the $19.4 million loss in the same period of 2023. The company ended 2024 with $98.6 million in cash, cash equivalents, and investments, which is expected to fund operations into Q4 2026. Research and development expenses decreased, while general and administrative expenses saw a slight increase.

Black Diamond Therapeutics reported its third quarter 2024 financial results, highlighting encouraging initial Phase 2 data of BDTX-1535 in recurrent EGFRm NSCLC and a corporate restructuring to prioritize BDTX-1535 development and extend cash runway into Q2 2026.

Black Diamond Therapeutics reported a net loss of $19.9 million for the second quarter of 2024, with $123.0 million in cash, cash equivalents, and investments, expected to fund operations into Q4 2025.

Black Diamond Therapeutics reported a net loss of $18.2 million for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $115.2 million as of March 31, 2024, which is expected to fund operations into Q3 2025.

Black Diamond Therapeutics reported a net loss of $19.4 million for the fourth quarter of 2023. The company's cash, cash equivalents, and investments totaled $131.4 million as of December 31, 2023, which is expected to fund operations into the second quarter of 2025.

Black Diamond Therapeutics reported its third quarter 2023 financial results. The company's cash, cash equivalents, and investments totaled $144.3 million as of September 30, 2023, which is expected to fund operations into the first half of 2025. BDTX-1535 Phase 1 dose escalation data showed durable anti-tumor activity and favorable safety profile in NSCLC patients. The first patient was dosed in a Phase 1 trial of BDTX-4933.

Black Diamond Therapeutics reported positive initial clinical data for BDTX-1535 and initiated NSCLC expansion cohorts. The company's cash position was strengthened by a recent public offering, providing funding into the first half of 2025.

Black Diamond Therapeutics reported a net loss of $20.9 million for the first quarter of 2023, with cash, cash equivalents, and investments totaling $103.4 million. The company is focused on advancing its pipeline programs, BDTX-1535 and BDTX-4933, and expects its current cash reserves to fund operations into the third quarter of 2024.

Black Diamond Therapeutics reported a net loss of $21.1 million for Q4 2022, compared to a net loss of $25.9 million for the same period in 2021. The company's cash, cash equivalents, and investments totaled $122.8 million as of December 31, 2022, expected to fund operations into the third quarter of 2024. They are on track to provide a clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in the second half of 2023.

Black Diamond Therapeutics reported a net loss of $21.7 million for the third quarter of 2022, with cash, cash equivalents, and investments of $144.2 million as of September 30, 2022. The company is focusing on advancing its lead programs and leveraging its MAP Drug Discovery Engine.

Black Diamond Therapeutics reported a net loss of $22.9 million for the second quarter of 2022. The company's cash, cash equivalents, and investments were approximately $160.9 million as of June 30, 2022, expected to be sufficient to fund operations into the third quarter of 2024.

Black Diamond Therapeutics reported its Q1 2022 financial results, highlighting the dosing of the first patient in the Phase 1 study of BDTX-1535 and the extension of the cash runway into Q3 2024 through pipeline prioritization and resource realignment. The company's cash, cash equivalents, and investments amounted to approximately $179.7 million as of March 31, 2022.

Black Diamond Therapeutics reported a net loss of $25.9 million for Q4 2021, compared to a net loss of $22.6 million for the same period in 2020. The company's cash, cash equivalents, and investments totaled $209.8 million as of December 31, 2021, which is expected to fund operations into 2024.

Black Diamond Therapeutics reported $235.0 million in cash, cash equivalents, and investments as of September 30, 2021. Net cash used in operations was $26.5 million for the third quarter of 2021. Research and development expenses were $27.6 million, and general and administrative expenses were $7.7 million for the third quarter of 2021.

Black Diamond Therapeutics reported its Q2 2021 financial results, highlighting the advancement of its clinical and pre-clinical pipeline, including BDTX-189, BDTX-1535, BRAF, and FGFR programs. The company's cash, cash equivalents, and investments totaled $263.5 million as of June 30, 2021.

Black Diamond Therapeutics reported $290.1 million in cash, cash equivalents, and investments as of March 31, 2021. Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections. Initial Phase 1 clinical data for BDTX-189 will be presented at ASCO Annual Meeting.

Black Diamond Therapeutics reported its fourth quarter and full year 2020 financial results, highlighting key progress in its clinical programs, including the ongoing Phase 1/2 trial of BDTX-189 and the advancement of BDTX-1535 into IND-enabling studies. The company's cash position is expected to fund operations into 2023.

Black Diamond Therapeutics reported $333.1 million in cash, cash equivalents, and investments as of September 30, 2020. The company is progressing with its Phase 1/2 clinical trial of BDTX-189 and strengthened its leadership team with key appointments.

Black Diamond Therapeutics reported financial results for the second quarter ended June 30, 2020. The company's cash, cash equivalents, and investments totaled $345.0 million. R&D expenses were $10.2 million, and G&A expenses were $4.9 million.

Black Diamond Therapeutics reported $357.2 million in cash and cash equivalents as of March 31, 2020. The company completed its initial public offering in February 2020, raising $231.3 million in gross proceeds. They also continued to enroll and dose patients in the Phase 1/2 clinical trial of BDTX-189.

Black Diamond Therapeutics reported its Q4 and full year 2019 financial results. The FDA allowed the IND application for BDTX-189, and the company initiated a Phase 1/2 clinical trial. Black Diamond believes that the $316 million raised since November, including via its IPO, will enable them to execute the clinical development of BDTX-189, continue to invest in their MAP platform, and progress their early stage pipeline.